{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T10:05:31Z","timestamp":1782036331544,"version":"3.54.5"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.<\/jats:p><\/jats:sec>Objective<\/jats:title>To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prespecified secondary analysis of the Diuretic Comparison Project, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, was conducted between June 1, 2016, and June 1, 2022, through Veterans Affairs facilities nationwide. This analysis extended follow-up to December 31, 2023. Veterans 65 years or older with hypertension who were taking hydrochlorothiazide were included.<\/jats:p><\/jats:sec>Intervention<\/jats:title>The Diuretic Comparison Project randomized 13\u202f523 participants to continue hydrochlorothiazide or switch to chlorthalidone.<\/jats:p><\/jats:sec>Main Outcome and Measures<\/jats:title>The main kidney outcome was CKD progression, defined as doubling of serum creatinine level from baseline, a terminal estimated glomerular filtration rate (eGFR) less than 15 mL\/min, or dialysis initiation.<\/jats:p><\/jats:sec>Results<\/jats:title>Analysis included 12\u202f265 participants (90.7%) with a baseline and 1 or more follow-up creatinine measurements (median [IQR] age, 71 [69-75] years; 3.2% female and 96.8% male). The mean (SD) study duration was 3.9 (1.3) years. Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 of 6118 [6.0%] vs 396 of 6147 [6.4%]; hazard ratio [HR], 0.94; 95% CI, 0.81-1.08; P<\/jats:italic>\u2009=\u2009.37). Similar results were observed when a 40% or greater reduction of eGFR was substituted for doubling of creatinine in the above outcome, as well as any of the components of the primary composite outcome. There was no difference in the incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P<\/jats:italic>\u2009=\u2009.59) or acute kidney injury requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P<\/jats:italic>\u2009=\u2009.63) between groups. However, a statistically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9%]; P<\/jats:italic>\u2009&amp;lt;\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associated with an increased risk for hypokalemia. Given these findings, clinicians should feel confident using either agent for the treatment of hypertension and kidney outcomes.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02185417<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.49576","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:24:57Z","timestamp":1733847897000},"page":"e2449576","source":"Crossref","is-referenced-by-count":4,"title":["Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension"],"prefix":"10.1001","volume":"7","author":[{"given":"Areef","family":"Ishani","sequence":"first","affiliation":[{"name":"Minneapolis Veterans Affairs (VA) Healthcare System, Minneapolis, Minnesota"},{"name":"Department of Medicine, University of Minnesota, Minneapolis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Hau","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Raju","sequence":"additional","affiliation":[{"name":"Minneapolis Veterans Affairs (VA) Healthcare System, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica K.","family":"Wise","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Glassman","sequence":"additional","affiliation":[{"name":"Pharmacy Benefits Management Services, Department of Veterans Affairs, Washington, DC"},{"name":"VA Greater Los Angeles Healthcare System, Los Angeles, California"},{"name":"David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison A.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Michael E. DeBakey VA Medical Center, Houston, Texas"},{"name":"Department of Medicine, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan E.","family":"Ferguson","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Medicine, Boston University Chobanian and Avedisian School of Medicine, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Cushman","sequence":"additional","affiliation":[{"name":"Medical Service, Memphis VA Medical Center, Memphis, Tennessee"},{"name":"Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Leatherman","sequence":"additional","affiliation":[{"name":"Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts"},{"name":"Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"issue":"19","key":"zoi241383r1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.010278","article-title":"Extracellular fluid volume is an independent determinant of uncontrolled and resistant hypertension in chronic kidney disease: a NephroTest cohort study.","volume":"7","author":"Vidal-Petiot","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"zoi241383r2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000343412","article-title":"Associations of proteinuria, fluid volume imbalance, and body mass index with circadian ambulatory blood pressure in chronic kidney disease patients.","volume":"36","author":"Ohashi","year":"2012","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"zoi241383r3","doi-asserted-by":"publisher","first-page":"A8","DOI":"10.1053\/j.ajkd.2022.12.001","article-title":"US Renal Data System 2022 annual data report: epidemiology of kidney disease in the United States.","volume":"81","author":"Johansen","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"zoi241383r4","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1161\/HYP.0000000000000065","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"issue":"8","key":"zoi241383r5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"issue":"6","key":"zoi241383r6","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2215\/CJN.07800811","article-title":"Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.","volume":"7","author":"Rahman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"zoi241383r7","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamainternmed.2019.7454","article-title":"Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension.","volume":"180","author":"Hripcsak","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"23","key":"zoi241383r8","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"issue":"24","key":"zoi241383r9","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1001\/jama.1991.03460240051027","article-title":"Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension; final results of the Systolic Hypertension in the Elderly Program (SHEP).","volume":"265","author":"SHEP Cooperative Research Group","year":"1991","journal-title":"JAMA"},{"issue":"6","key":"zoi241383r10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.7326\/0003-4819-158-6-201303190-00004","article-title":"Chlorthalidone versus hydrochlorothiazide for the treatment of hypertension in older adults: a population-based cohort study.","volume":"158","author":"Dhalla","year":"2013","journal-title":"Ann Intern Med"},{"issue":"9","key":"zoi241383r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.23365","article-title":"Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function.","volume":"4","author":"Edwards","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"26","key":"zoi241383r12","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","article-title":"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events.","volume":"387","author":"Ishani","year":"2022","journal-title":"N Engl J Med"},{"key":"zoi241383r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.106754","article-title":"Design of a pragmatic clinical trial embedded in the Electronic Health Record: the VA\u2019s Diuretic Comparison Project.","volume":"116","author":"Ishani","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"zoi241383r14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2023.107239","article-title":"Telephone informed consent in a pragmatic point-of-care clinical trial embedded in primary care.","volume":"131","author":"Klint","year":"2023","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"zoi241383r15","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"issue":"12","key":"zoi241383r16","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA).","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"issue":"3S","key":"zoi241383r17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"issue":"3","key":"zoi241383r18","doi-asserted-by":"publisher","first-page":"172","DOI":"10.7326\/0003-4819-144-3-200602070-00005","article-title":"Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.","volume":"144","author":"Rahman","year":"2006","journal-title":"Ann Intern Med"},{"key":"zoi241383r19","doi-asserted-by":"publisher","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"issue":"27","key":"zoi241383r20","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","article-title":"Chlorthalidone for hypertension in advanced chronic kidney disease.","volume":"385","author":"Agarwal","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi241383r21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.amjhyper.2004.12.007","article-title":"Is population-wide diuretic use directly associated with the incidence of end-stage renal disease in the United States? a hypothesis.","volume":"18","author":"Hawkins","year":"2005","journal-title":"Am J Hypertens"},{"issue":"6","key":"zoi241383r22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s10157-017-1397-6","article-title":"Outcomes of diuretic use in pre-dialysis CKD patients with moderate renal deterioration attending tertiary care referral center.","volume":"21","author":"Khan","year":"2017","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"zoi241383r23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/ndt\/gfh650","article-title":"A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension.","volume":"20","author":"Dussol","year":"2005","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"zoi241383r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-048755","article-title":"Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study.","volume":"12","author":"Fitzpatrick","year":"2022","journal-title":"BMJ Open"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2827625\/ishani_2024_oi_241383_1732741428.2559.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T16:25:01Z","timestamp":1733847901000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2827625"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.49576","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]}}}